SCHEMBL21829964

SCHEMBL21829964

CC(C)N1CC(=O)N(Cc2ccc(C#N)cc2)C(c2ccc(Cl)cc2)C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 1/20 0.41
MDM2 Q00987 6/20 0.40
TP53 P04637 5/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
ALDH1A1 P00352 3/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.37
LMNA P02545 1/20 0.37
ANXA2 P07355 1/20 0.36
S100A10 P60903 1/20 0.36
FNTA P49354 2/20 0.36
FNTB P49356 2/20 0.36
PGGT1B P53609 2/20 0.36
NSD2 O96028 1/20 0.35
CYP1A2 P05177 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21778041 0.91 TP53 (0.45) MDM2TP53ALDH1A1MEN1GAA
SCHEMBL21829590 0.91 TP53 (0.45) MDM2TP53ALDH1A1MEN1GAA
SCHEMBL21864982 0.91 TP53 (0.45) MDM2TP53ALDH1A1MEN1GAA
SCHEMBL29789211 0.89 MDM2 (0.43) MDM2TP53ALDH1A1MEN1KMT2A
SCHEMBL21830863 0.89 MDM2 (0.43) MDM2TP53ALDH1A1MEN1KMT2A
SCHEMBL21829922 0.86 TP53 (0.52) MDM2TP53ALDH1A1MEN1GAA
SCHEMBL21830161 0.85 TP53 (0.53) TP53ALDH1A1MEN1GAAKMT2A
SCHEMBL21830494 0.85 TP53 (0.53) TP53ALDH1A1MEN1GAAKMT2A
SCHEMBL21829766 0.85 ALDH1A1 (0.50) MDM2TP53ALDH1A1MEN1KMT2A
SCHEMBL21865006 0.83 ALDH1A1 (0.54) TP53ALDH1A1MEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250276976-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2025-09-04 US disclosed
US-12275741-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2025-04-15 US disclosed
US-20240368172-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2024-11-07 US disclosed
US-11952381-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2024-04-09 US disclosed
US-20230090256-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2023-03-23 US disclosed
US-11414424-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2022-08-16 US disclosed
US-11414424-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2022-08-16 US disclosed
US-20200109148-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2020-04-09 US disclosed
US-20200109148-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2020-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11414424-B2 Cardiac sarcomere inhibitors TNNI3, MYLK2, TNNT2 P2RX3 3978/4885MDM2 4490/4885TP53 4830/4885
US-20200109148-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, MYLK2, TNNT2 P2RX3 3978/4885MDM2 4490/4885TP53 4830/4885
US-20230090256-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, MYLK2, TNNT2 P2RX3 3978/4885MDM2 4490/4885TP53 4830/4885
US-12275741-B2 Cardiac sarcomere inhibitors TNNI3, MYLK2, TNNT2 P2RX3 3978/4885MDM2 4490/4885TP53 4830/4885
US-20240368172-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, MYLK2, TNNT2 P2RX3 3978/4885MDM2 4490/4885TP53 4830/4885
US-20250276976-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, MYLK2, TNNT2 P2RX3 3978/4885MDM2 4490/4885TP53 4830/4885
US-11952381-B2 Cardiac sarcomere inhibitors TNNI3, MYLK2, TNNT2 P2RX3 3978/4885MDM2 4490/4885TP53 4830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.